Viva Biotech

Executive Summary

Viva Biotech is a leading Chinese contract research organization (CRO) specializing in early-stage drug discovery, with a strong emphasis on structural biology, artificial intelligence, and medicinal chemistry. Founded in 2008 and headquartered in Shanghai, the company serves a global client base across oncology, infectious disease, and neurology. Viva differentiates itself through its proprietary structure-based drug discovery platform, which leverages advanced cryo-electron microscopy (cryo-EM) and X-ray crystallography to accelerate target identification and lead optimization. The company also operates a unique partnership fund model, investing in promising biotech startups in exchange for future service contracts, thereby creating a self-reinforcing ecosystem that drives both revenue and innovation. As a publicly traded entity, Viva Biotech benefits from strong tailwinds in the global CRO market, particularly the increasing outsourcing of R&D by pharmaceutical companies seeking cost-effective solutions. Its focus on AI-enabled drug design and structural biology positions it well to capture demand for more efficient and precise drug development processes.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new AI-driven drug discovery collaborations with major pharma70% success
• Q1 2027IPO or major funding round for a key portfolio company40% success
• Q4 2026Publication of positive preclinical data from a client program using Viva's platform60% success